LUNAR IIIb Study Comparing Rosuvastatin and Atorvastatin in Subjects With Acute Coronary Syndromes

NCT ID: NCT00214630

Last Updated: 2010-11-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

825 participants

Study Classification

INTERVENTIONAL

Study Start Date

2003-12-31

Study Completion Date

2007-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Comparison of rosuvastatin and atorvastatin in subjects with acute coronary syndromes

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Acute Coronary Syndromes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

rosuvastatin calcium

Intervention Type DRUG

atorvastatin

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Crestor Lipitor

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Non-ST segment elevation ACS and ST segment elevation ACS who receive optimal reperfusion therapy

Exclusion Criteria

* Previous Q-wave infarct within the last 4 weeks
* CK elevation not caused by myocardial injury
* uncontrolled hypertension at time of randomization
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

AstraZeneca Crestor Medical Science Director, MD

Role: STUDY_DIRECTOR

AstraZeneca

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

San Diego, California, United States

Site Status

Research Site

Torrance, California, United States

Site Status

Research Site

Bridgeport, Connecticut, United States

Site Status

Research Site

Atlantis, Florida, United States

Site Status

Research Site

Brandon, Florida, United States

Site Status

Research Site

Jacksonville, Florida, United States

Site Status

Research Site

Pensacola, Florida, United States

Site Status

Research Site

Safety Harbor, Florida, United States

Site Status

Research Site

Tampa, Florida, United States

Site Status

Research Site

Aurora, Illinois, United States

Site Status

Research Site

Chicago, Illinois, United States

Site Status

Research Site

Lombard, Illinois, United States

Site Status

Research Site

Melrose Park, Illinois, United States

Site Status

Research Site

Peoria, Illinois, United States

Site Status

Research Site

Anderson, Indiana, United States

Site Status

Research Site

Indianapolis, Indiana, United States

Site Status

Research Site

Des Moines, Iowa, United States

Site Status

Research Site

Louisville, Kentucky, United States

Site Status

Research Site

Owensboro, Kentucky, United States

Site Status

Research Site

Covington, Louisiana, United States

Site Status

Research Site

Shreveport, Louisiana, United States

Site Status

Research Site

Annapolis, Maryland, United States

Site Status

Research Site

Towson, Maryland, United States

Site Status

Research Site

Ann Arbor, Michigan, United States

Site Status

Research Site

Pontiac, Michigan, United States

Site Status

Research Site

Troy, Michigan, United States

Site Status

Research Site

Minneapolis, Minnesota, United States

Site Status

Research Site

Saint Paul, Minnesota, United States

Site Status

Research Site

Tupelo, Mississippi, United States

Site Status

Research Site

Kansas City, Missouri, United States

Site Status

Research Site

St Louis, Missouri, United States

Site Status

Research Site

Kalispell, Montana, United States

Site Status

Research Site

Newark, New Jersey, United States

Site Status

Research Site

Albuquerque, New Mexico, United States

Site Status

Research Site

Rochester, New York, United States

Site Status

Research Site

Asheville, North Carolina, United States

Site Status

Research Site

Cincinnati, Ohio, United States

Site Status

Research Site

Fairview Park, Ohio, United States

Site Status

Research Site

Springfield, Ohio, United States

Site Status

Research Site

Oklahoma City, Oklahoma, United States

Site Status

Research Site

Tulsa, Oklahoma, United States

Site Status

Research Site

Bend, Oregon, United States

Site Status

Research Site

Portland, Oregon, United States

Site Status

Research Site

Danville, Pennsylvania, United States

Site Status

Research Site

Memphis, Tennessee, United States

Site Status

Research Site

Amarillo, Texas, United States

Site Status

Research Site

Beaumont, Texas, United States

Site Status

Research Site

Dallas, Texas, United States

Site Status

Research Site

Lubbock, Texas, United States

Site Status

Research Site

Chesapeake, Virginia, United States

Site Status

Research Site

Burien, Washington, United States

Site Status

Research Site

Wausau, Wisconsin, United States

Site Status

Research Site

San José, , Costa Rica

Site Status

Research Site

San Salvador, , El Salvador

Site Status

Research Site

Ayer, , Morocco

Site Status

Research Site

Panama City, , Panama

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Costa Rica El Salvador Morocco Panama

References

Explore related publications, articles, or registry entries linked to this study.

Pitt B, Loscalzo J, Ycas J, Raichlen JS. Lipid levels after acute coronary syndromes. J Am Coll Cardiol. 2008 Apr 15;51(15):1440-5. doi: 10.1016/j.jacc.2007.11.075.

Reference Type DERIVED
PMID: 18402897 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

D3560L00021

Identifier Type: -

Identifier Source: secondary_id

LUNAR

Identifier Type: -

Identifier Source: secondary_id

4522US/0001

Identifier Type: -

Identifier Source: org_study_id